

Yoon-La Choi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1670167/publications.pdf>

Version: 2024-02-01

183
papers

6,105
citations

61945

43
h-index

102432

66
g-index

183
all docs

183
docs citations

183
times ranked

10247
citing authors

#	ARTICLE	IF	CITATIONS
1	Interlaboratory Comparison Study (Ring Test) of Next-Generation Sequencing-Based NTRK Fusion Detection in South Korea. <i>Cancer Research and Treatment</i> , 2023, 55, 28-40.	1.3	4
2	Analysis of PIK3CA Mutation Concordance and Frequency in Primary and Different Distant Metastatic Sites in Breast Cancer. <i>Cancer Research and Treatment</i> , 2023, 55, 145-154.	1.3	2
3	Trimodality therapy for locally advanced esophageal squamous cell carcinoma: the role of volume-based PET/CT in patient management and prognostication. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 751-762.	3.3	5
4	Selection Strategies and Practical Application of BRAF V600E-Mutated Non-Small Cell Lung Carcinoma. <i>Cancer Research and Treatment</i> , 2022, 54, 782-792.	1.3	3
5	Matrix metalloproteinase 11 (MMP11) in macrophages promotes the migration of HER2-positive breast cancer cells and monocyte recruitment through CCL2-CCR2 signaling. <i>Laboratory Investigation</i> , 2022, 102, 376-390.	1.7	24
6	Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 2321-2328.	3.2	7
7	Abstract PD2-08: Serial genomic profiling reveals molecular mechanisms of breast cancer resistance to palbociclib. <i>Cancer Research</i> , 2022, 82, PD2-08-PD2-08.	0.4	1
8	Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. <i>Cancer</i> , 2022, 128, 2148-2158.	2.0	19
9	Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1916-1928.	0.8	94
10	Prognostic impact of micropapillary and solid histological subtype on patients undergoing curative resection for stage I lung adenocarcinoma according to the extent of pulmonary resection and lymph node assessment. <i>Lung Cancer</i> , 2022, 168, 21-29.	0.9	5
11	Expression of SLC22A18 regulates oxaliplatin resistance by modulating the ERK pathway in colorectal cancer. <i>American Journal of Cancer Research</i> , 2022, 12, 1393-1408.	1.4	0
12	Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer. <i>European Journal of Cancer</i> , 2022, 169, 42-53.	1.3	10
13	Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response. <i>European Journal of Cancer</i> , 2022, 170, 17-26.	1.3	21
14	The inflamed immune phenotype (IIP): A clinically actionable artificial intelligence (AI)-based biomarker predictive of immune checkpoint inhibitor (ICI) outcomes across 16 primary tumor types. <i>Journal of Clinical Oncology</i> , 2022, 40, 2621-2621.	0.8	1
15	Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer. <i>JAMA Oncology</i> , 2022, 8, 1271.	3.4	15
16	Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC. <i>Clinical Cancer Research</i> , 2022, 28, 4312-4321.	3.2	7
17	Second primary pleomorphic carcinoma arising from the pneumonectomy cavity of non-small cell lung cancer: A case report. <i>Respiratory Medicine Case Reports</i> , 2021, 32, 101373.	0.2	0
18	TM4SF4 and LRRK2 Are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis. <i>Cancer Research and Treatment</i> , 2021, 53, 9-24.	1.3	11

#	ARTICLE	IF	CITATIONS
19	High concordance of actionable genomic alterations identified between circulating tumor DNAâ€‘based and tissueâ€‘based nextâ€‘generation sequencing testing in advanced nonâ€‘small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. <i>Cancer</i> , 2021, 127, 3019-3028.	2.0	37
20	Mitochondrial DNA Copy Number Assist with Diagnosis of Vague Myopathy. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
21	Distinct subset of immune cells assessed by multiplex immunohistochemistry correlates with immune phenotype classified by an artificial intelligence-powered tissue analyzer in advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21012-e21012.	0.8	0
22	Molecular biomarker testing for nonâ€‘small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group. <i>Journal of Pathology and Translational Medicine</i> , 2021, 55, 181-191.	0.4	10
23	Overexpression of Replication-Dependent Histone Signifies a Subset of Dedifferentiated Liposarcoma with Increased Aggressiveness. <i>Cancers</i> , 2021, 13, 3122.	1.7	7
24	Real-World Analysis of the EGFR Mutation Test in Tissue and Plasma Samples from Non-Small Cell Lung Cancer. <i>Diagnostics</i> , 2021, 11, 1695.	1.3	3
25	PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score. <i>Cancers</i> , 2021, 13, 4659.	1.7	20
26	Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4671-4692.	1.0	6
27	<sc> <i>NTRK</i> oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions. <i>Journal of Pathology</i> , 2021, 255, 399-411.	2.1	8
28	Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment. <i>Translational Lung Cancer Research</i> , 2021, 10, 4209-4220.	1.3	6
29	Lung Cancer in Korea. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1988-1993.	0.5	5
30	Nomogram for prediction of lymph node metastasis in patients with superficial esophageal squamous cell carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1009-1015.	1.4	27
31	Soft tissue sarcoma: DWI and DCE-MRI parameters correlate with Ki-67 labeling index. <i>European Radiology</i> , 2020, 30, 914-924.	2.3	42
32	Development of Human Monoclonal Antibody for Claudin-3 Overexpressing Carcinoma Targeting. <i>Biomolecules</i> , 2020, 10, 51.	1.8	7
33	Junction Location Identifier (JuLI). <i>Journal of Molecular Diagnostics</i> , 2020, 22, 304-318.	1.2	6
34	Benefit of Targeted DNA Sequencing in Advanced Nonâ€‘Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. <i>Clinical Lung Cancer</i> , 2020, 21, e182-e190.	1.1	5
35	Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. , 2020, 8, e001199.		7
36	Clinicopathological characteristics of primary lung nuclear protein in testis carcinoma: A singleâ€‘institute experience of 10 cases. <i>Thoracic Cancer</i> , 2020, 11, 3205-3212.	0.8	15

#	ARTICLE	IF	CITATIONS
37	Earlier-Phased Cancer Immunity Cycle Strongly Influences Cancer Immunity in Operable Never-Smoker Lung Adenocarcinoma. <i>IScience</i> , 2020, 23, 101386.	1.9	5
38	Clinicoradiopathological features and prognosis according to genomic alterations in patients with resected lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2020, 12, 5357-5368.	0.6	8
39	Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. <i>Nature Communications</i> , 2020, 11, 6175.	5.8	92
40	Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. <i>Nature Communications</i> , 2020, 11, 2285.	5.8	565
41	Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer. <i>Cancers</i> , 2020, 12, 1575.	1.7	8
42	An Immune-Magnetophoretic Device for the Selective and Precise Enrichment of Circulating Tumor Cells from Whole Blood. <i>Micromachines</i> , 2020, 11, 560.	1.4	12
43	Dysregulation of cancer genes by recurrent intergenic fusions. <i>Genome Biology</i> , 2020, 21, 166.	3.8	22
44	UBE2C Overexpression Aggravates Patient Outcome by Promoting Estrogen-Dependent/Independent Cell Proliferation in Early Hormone Receptor-Positive and HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 9, 1574.	1.3	27
45	IRS2 Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer. <i>Molecular Therapy - Oncolytics</i> , 2020, 16, 188-196.	2.0	6
46	Current status and future perspectives of liquid biopsy in non-small cell lung cancer. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 204-212.	0.4	17
47	Molecular changes in solitary fibrous tumor progression. <i>Journal of Molecular Medicine</i> , 2019, 97, 1413-1425.	1.7	47
48	Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 667.	1.3	12
49	Adipogenesis induces growth inhibition of dedifferentiated liposarcoma. <i>Cancer Science</i> , 2019, 110, 2676-2683.	1.7	14
50	Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. <i>European Journal of Cancer</i> , 2019, 120, 65-74.	1.3	33
51	Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4794.	1.8	29
52	Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients. <i>Clinical Lung Cancer</i> , 2019, 20, e309-e316.	1.1	11
53	Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 193-202.	0.5	104
54	Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology. <i>Laboratory Investigation</i> , 2019, 99, 1309-1320.	1.7	16

#	ARTICLE	IF	CITATIONS
55	Capsule biopsy of acellular dermal matrix (ADM) to predict future capsular contracture in two-stage prosthetic breast reconstruction. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2019, 72, 1576-1606.	0.5	6
56	Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers. <i>Pathology Research and Practice</i> , 2019, 215, 152441.	1.0	12
57	Identification of tumor suppressor miRNAs by integrative miRNA and mRNA sequencing of matched tumor-normal samples in lung adenocarcinoma. <i>Molecular Oncology</i> , 2019, 13, 1356-1368.	2.1	39
58	Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer. <i>Lung Cancer</i> , 2019, 130, 87-92.	0.9	39
59	Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists. <i>Journal of Pathology and Translational Medicine</i> , 2019, 53, 347-353.	0.4	24
60	High expression of NR1D1 is associated with good prognosis in triple-negative breast cancer patients treated with chemotherapy. <i>Breast Cancer Research</i> , 2019, 21, 127.	2.2	16
61	High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma. <i>Scientific Reports</i> , 2019, 9, 20197.	1.6	15
62	EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy. <i>Cancer Research and Treatment</i> , 2019, 51, 493-501.	1.3	30
63	Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea. <i>Cancer Research and Treatment</i> , 2019, 51, 623-631.	1.3	40
64	Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer. <i>Cancer Biology and Therapy</i> , 2018, 19, 335-345.	1.5	19
65	Droplet digital PCR-based EGFR mutation detection with an internal quality control index to determine the quality of DNA. <i>Scientific Reports</i> , 2018, 8, 543.	1.6	16
66	Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. <i>Nature Communications</i> , 2018, 9, 1725.	5.8	122
67	Clinical benefit and residual kidney function of en bloc nephrectomy for perirenal retroperitoneal sarcoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e465-e471.	0.7	4
68	Radical Nephrectomy for Primary Retroperitoneal Liposarcoma Near the Kidney has a Beneficial Effect on Disease-Free Survival. <i>World Journal of Surgery</i> , 2018, 42, 254-262.	0.8	9
69	Status of programmed death-ligand 1 expression in sarcomas. <i>Journal of Translational Medicine</i> , 2018, 16, 303.	1.8	33
70	Integrin β 3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in <i>ALK</i> -Rearranged NSCLC. <i>Clinical Cancer Research</i> , 2018, 24, 4162-4174.	3.2	13
71	Genomic alterations of ground-glass nodular lung adenocarcinoma. <i>Scientific Reports</i> , 2018, 8, 7691.	1.6	10
72	Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma. <i>Lung Cancer</i> , 2018, 122, 160-164.	0.9	10

#	ARTICLE	IF	CITATIONS
73	Sigmoid colon perforation after postoperative hypofractionated intensity-modulated radiation therapy in a cervical cancer patient. <i>Cancer Reports</i> , 2018, 1, e1129.	0.6	1
74	Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors. <i>Journal of Korean Medical Science</i> , 2018, 33, e123.	1.1	5
75	Abrupt Dyskeratotic and Squamoid Cells in Poorly Differentiated Carcinoma: Case Study of Two Thoracic NUT Midline Carcinomas with Cytohistologic Correlation. <i>Journal of Pathology and Translational Medicine</i> , 2018, 52, 349-353.	0.4	12
76	Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2018, 50, 95-102.	1.3	22
77	Clinical outcomes of EGFR exon 20 insertion in advanced NSCLC in Korea.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21136-e21136.	0.8	0
78	Outcomes of Curative-intent Surgery and Adjuvant Treatment for Pulmonary Large Cell Neuroendocrine Carcinoma. <i>World Journal of Surgery</i> , 2017, 41, 1820-1827.	0.8	33
79	Integrated genomic analysis of recurrence-associated small non-coding RNAs in oesophageal cancer. <i>Gut</i> , 2017, 66, 215-225.	6.1	34
80	Genomic profiling of esophageal squamous cell carcinoma (ESCC)â€”Basis for precision medicine. <i>Pathology Research and Practice</i> , 2017, 213, 836-841.	1.0	16
81	A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2âˆ’ early breast cancer. <i>Scientific Reports</i> , 2017, 7, 45554.	1.6	26
82	MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 41-56.	1.1	51
83	MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1233-1246.	0.5	68
84	Systematic identification of cancer-related long noncoding RNAs and aberrant alternative splicing of quintuple-negative lung adenocarcinoma through RNA-Seq. <i>Lung Cancer</i> , 2017, 109, 21-27.	0.9	26
85	Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of <i>BRAF</i> ^{V600E} Mutation. <i>Thyroid</i> , 2017, 27, 802-810.	2.4	78
86	Girdin protein expression is associated with poor prognosis in patients with invasive breast cancer. <i>Pathology</i> , 2017, 49, 618-626.	0.3	14
87	Therapeutic strategies for locally recurrent and metastatic de-differentiated liposarcoma with herpes simplex virusâ€”thymidine kinaseâ€”expressing mesenchymal stromal cells. <i>Cytotherapy</i> , 2017, 19, 1035-1047.	0.3	6
88	Programmed Death Ligand 1 Expression in Paired Nonâ€”Small Cell Lung Cancer Tumor Samples. <i>Clinical Lung Cancer</i> , 2017, 18, e473-e479.	1.1	35
89	Effect of HPV E6/E7 siRNA with Chemotherapeutic Agents on the Regulation of TP53/E2F Dynamic Behavior for Cell Fate Decisions. <i>Neoplasia</i> , 2017, 19, 735-749.	2.3	14
90	Diagnostic Limitation of Fine-Needle Aspiration (FNA) on Indeterminate Thyroid Nodules Can Be Partially Overcome by Preoperative Molecular Analysis: Assessment of RET/PTC1 Rearrangement in BRAF and RAS Wild-Type Routine Air-Dried FNA Specimens. <i>International Journal of Molecular Sciences</i> , 2017, 18, 806.	1.8	12

#	ARTICLE	IF	CITATIONS
91	Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification. <i>BMC Cancer</i> , 2017, 17, 535.	1.1	3
92	Molecular Testing of Lung Cancers. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 242-254.	0.4	26
93	Good Laboratory Standards for Clinical Next-Generation Sequencing Cancer Panel Tests. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 191-204.	0.4	42
94	Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients. <i>Oncotarget</i> , 2017, 8, 61538-61550.	0.8	28
95	Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (<i>ALK</i>) rearranged non-small cell lung cancer. <i>Journal of Pathology</i> , 2017, 243, 307-319.	2.1	63
96	Unforeseen clonal evolution of tumor cell population in recurrent and metastatic dermatofibrosarcoma protuberans. <i>PLoS ONE</i> , 2017, 12, e0185826.	1.1	10
97	Comparison of retroperitoneal liposarcoma extending into the inguinal canal and inguinoscrotal liposarcoma. <i>Canadian Journal of Surgery</i> , 2017, 60, 399-407.	0.5	9
98	<i>KRAS</i> mutation analysis of washing fluid from endoscopic ultrasound-guided fine needle aspiration improves cytologic diagnosis of pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 3519-3527.	0.8	11
99	Genes co-amplified with <i>ERBB2</i> or <i>MET</i> as novel potential cancer-promoting genes in gastric cancer. <i>Oncotarget</i> , 2017, 8, 92209-92226.	0.8	26
100	Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 441-443.	0.4	9
101	Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies. <i>Cancer Research and Treatment</i> , 2017, 49, 915-926.	1.3	58
102	Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients. <i>Cancer Research and Treatment</i> , 2017, 49, 1065-1076.	1.3	11
103	Quantitative image variables reflect the intratumoral pathologic heterogeneity of lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 67302-67313.	0.8	76
104	The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. <i>Journal of Thoracic Disease</i> , 2016, 8, 3175-3186.	0.6	4
105	Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with <i>FGFR1</i> amplification: A single-arm, phase 2 study. <i>Cancer</i> , 2016, 122, 3024-3031.	2.0	72
106	Prognostic Significance of <i>TERT</i> Promoter Mutations in Papillary Thyroid Carcinomas in a <i>BRAF^{V600E}</i> Mutation-Prevalent Population. <i>Thyroid</i> , 2016, 26, 901-910.	2.4	69
107	Analyzing Somatic Genome Rearrangements in Human Cancers by Using Whole-Exome Sequencing. <i>American Journal of Human Genetics</i> , 2016, 98, 843-856.	2.6	33
108	Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2129-2140.	0.5	70

#	ARTICLE	IF	CITATIONS
109	Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1003-1011.	0.5	130
110	Efficiency of methylated DNA immunoprecipitation bisulphite sequencing for whole-genome DNA methylation analysis. <i>Epigenomics</i> , 2016, 8, 1061-1077.	1.0	11
111	Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment. <i>Journal of Thoracic Oncology</i> , 2016, 11, e1-e4.	0.5	76
112	Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, e45-e47.	0.5	98
113	Correlation of ERG immunohistochemistry with molecular detection of TMPRSS2-ERG gene fusion. <i>Journal of Clinical Pathology</i> , 2016, 69, 586-592.	1.0	13
114	ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare. <i>Lung Cancer</i> , 2016, 94, 22-27.	0.9	56
115	Mechanisms and Consequences of Cancer Genome Instability: Lessons from Genome Sequencing Studies. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2016, 11, 283-312.	9.6	106
116	A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement. <i>Journal of Clinical Oncology</i> , 2016, 34, 9013-9013.	0.8	16
117	Prognostic significance of survivin in rectal cancer patients treated with surgery and postoperative concurrent chemo-radiation therapy. <i>Oncotarget</i> , 2016, 7, 62676-62686.	0.8	6
118	LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients. <i>Oncotarget</i> , 2016, 7, 82876-82888.	0.8	11
119	Integrated genomic approaches identify upregulation of <i>SCRN1</i> as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation. <i>Oncotarget</i> , 2016, 7, 13797-13809.	0.8	7
120	Clinicopathologic characteristics of <i>EGFR</i> , <i>KRAS</i> , and <i>ALK</i> alterations in 6,595 lung cancers. <i>Oncotarget</i> , 2016, 7, 23874-23884.	0.8	62
121	<i>PIK3CA</i> amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 30691-30701.	0.8	28
122	Identification of a novel partner gene, <i>KIAA1217</i> , fused to <i>RET</i> : Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 36101-36114.	0.8	31
123	Non-small Cell Lung Cancer with Concomitant <i>EGFR</i> , <i>KRAS</i> , and <i>ALK</i> Mutation: Clinicopathologic Features of 12 Cases. <i>Journal of Pathology and Translational Medicine</i> , 2016, 50, 197-203.	0.4	73
124	Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases. <i>Journal of Pathology and Translational Medicine</i> , 2016, 50, 258-263.	0.4	50
125	<i>SEC31A-ALK</i> Fusion Gene in Lung Adenocarcinoma. <i>Cancer Research and Treatment</i> , 2016, 48, 398-402.	1.3	27
126	A novel histone deacetylase 6-selective inhibitor suppresses synovial inflammation and joint destruction in a collagen antibody-induced arthritis mouse model. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 514-523.	0.9	25

#	ARTICLE	IF	CITATIONS
127	Cytomorphological identification of advanced pulmonary adenocarcinoma harboring <sc>KRAS</sc> mutation in lymph node fine-needle aspiration specimens: Comparative investigation of adenocarcinoma with <sc>KRAS</sc> and <sc>EGFR</sc> mutations. <i>Diagnostic Cytopathology</i> , 2015, 43, 539-544.	0.5	5
128	Human Papillomavirus E6/E7-Specific siRNA Potentiates the Effect of Radiotherapy for Cervical Cancer in Vitro and in Vivo. <i>International Journal of Molecular Sciences</i> , 2015, 16, 12243-12260.	1.8	19
129	CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0139112.	1.1	78
130	Comparison of Accuracy of Whole-Exome Sequencing with Formalin-Fixed Paraffin-Embedded and Fresh Frozen Tissue Samples. <i>PLoS ONE</i> , 2015, 10, e0144162.	1.1	76
131	Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving <i>EGFR</i>. <i>Oncotarget</i> , 2015, 6, 5465-5474.	0.8	116
132	Anoctamin 1 (TMEM16A) is essential for testosterone-induced prostate hyperplasia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9722-9727.	3.3	53
133	Survival Outcome Assessed According to Tumor Burden and Progression Patterns in Patients With Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Undergoing Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. <i>Clinical Lung Cancer</i> , 2015, 16, 228-236.	1.1	23
134	Patient-Derived Xenografts from Non-Small Cell Lung Cancer Brain Metastases Are Valuable Translational Platforms for the Development of Personalized Targeted Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 1172-1182.	3.2	58
135	Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. <i>Journal of Clinical Oncology</i> , 2015, 33, 2660-2666.	0.8	215
136	Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma. <i>Modern Pathology</i> , 2015, 28, 468-479.	2.9	114
137	Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2015, 6, 2562-2572.	0.8	30
138	Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer. <i>Oncotarget</i> , 2015, 6, 32027-32038.	0.8	36
139	HER2 as a novel therapeutic target for cervical cancer. <i>Oncotarget</i> , 2015, 6, 36219-36230.	0.8	51
140	Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)-Expressing Pulmonary Adenocarcinoma. <i>Journal of Pathology and Translational Medicine</i> , 2015, 49, 310-317.	0.4	22
141	Targeted Inhibition of FAK, PYK2 and BCL-XL Synergistically Enhances Apoptosis in Ovarian Clear Cell Carcinoma Cell Lines. <i>PLoS ONE</i> , 2014, 9, e88587.	1.1	25
142	Quantitative CT Variables Enabling Response Prediction in Neoadjuvant Therapy with EGFR-TKIs: Are They Different from Those in Neoadjuvant Concurrent Chemoradiotherapy?. <i>PLoS ONE</i> , 2014, 9, e88598.	1.1	47
143	Polyostotic Fibrous Dysplasia Mimicking Multiple Bone Metastases in a Patient with Ductal Carcinoma In Situ. <i>Journal of Breast Cancer</i> , 2014, 17, 83.	0.8	5
144	Synchronous Triple Primary Lung Cancers: A Case Report. <i>Korean Journal of Radiology</i> , 2014, 15, 646.	1.5	8

#	ARTICLE	IF	CITATIONS
145	Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent <i>In Vitro</i> Antitumor Activity in Gastric Cancer Cell Lines with <i>FGFR2</i> Amplification. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2527-2536.	1.9	34
146	SMAD4 Suppresses AURKA-Induced Metastatic Phenotypes via Degradation of AURKA in a TGF β ² -Independent Manner. <i>Molecular Cancer Research</i> , 2014, 12, 1779-1795.	1.5	20
147	<i>KRAS</i> Mutation Detection in Non-small Cell Lung Cancer Using a Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping Method and Comparative Validation with Next-Generation Sequencing. <i>Korean Journal of Pathology</i> , 2014, 48, 100.	1.2	20
148	Extrapulmonary Lymphangioliomyoma: Clinicopathological Analysis of 4 Cases. <i>Korean Journal of Pathology</i> , 2014, 48, 188.	1.2	11
149	Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. <i>Lung Cancer</i> , 2014, 83, 259-264.	0.9	30
150	A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 229-243.	1.2	105
151	<i>FGFR3</i> overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 49.e23-49.e31.	0.8	34
152	The analysis of mutations and exon deletions at <i>TSC2</i> gene in angiomyolipomas associated with tuberous sclerosis complex. <i>Experimental and Molecular Pathology</i> , 2014, 97, 440-444.	0.9	5
153	Patterns of somatic alterations between matched primary and metastatic colorectal tumors characterized by whole-genome sequencing. <i>Genomics</i> , 2014, 104, 234-241.	1.3	58
154	Pleural epithelioid hemangioendothelioma harboring <i>CAMTA1</i> rearrangement. <i>Lung Cancer</i> , 2014, 83, 411-415.	0.9	21
155	Colorectal cancer patient-derived xenografted tumors maintain characteristic features of the original tumors. <i>Journal of Surgical Research</i> , 2014, 187, 502-509.	0.8	41
156	A Novel Fusion of <i>TPR</i> and <i>ALK</i> in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2014, 9, 563-566.	0.5	83
157	Aberrant <i>CDK4</i> Amplification in Refractory Rhabdomyosarcoma as Identified by Genomic Profiling. <i>Scientific Reports</i> , 2014, 4, 3623.	1.6	25
158	PD-L1 expression and survival in patients with non-small cell lung cancer (NSCLC) in Korea. <i>Journal of Clinical Oncology</i> , 2014, 32, 8066-8066.	0.8	9
159	<i>CDK4</i> Amplification Predicts Recurrence of Well-Differentiated Liposarcoma of the Abdomen. <i>PLoS ONE</i> , 2014, 9, e99452.	1.1	17
160	Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma. <i>Oncotarget</i> , 2014, 5, 9065-9078.	0.8	16
161	The presence of <i>ALK</i> translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series. <i>Journal of Clinical Oncology</i> , 2014, 32, e17048-e17048.	0.8	0
162	A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating <i>EGFR</i> mutations. <i>Journal of Clinical Oncology</i> , 2014, 32, e19155-e19155.	0.8	0

#	ARTICLE	IF	CITATIONS
163	High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma. <i>Histology and Histopathology</i> , 2014, 29, 127-38.	0.5	30
164	<scp>EGFR</scp> and <scp>KRAS</scp> mutation analyses from specimens obtained by bronchoscopy and <scp>EBUSâ€TBNA</scp>. <i>Thoracic Cancer</i> , 2013, 4, 264-272.	0.8	8
165	EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital. <i>PLoS ONE</i> , 2013, 8, e56011.	1.1	65
166	Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) patients who received taxane plus trastuzumab treatment.. <i>Journal of Clinical Oncology</i> , 2013, 31, 637-637.	0.8	0
167	A Dramatic Response to Crizotinib in a Nonâ€“Small-Cell Lung Cancer Patient with IHC-Positive and FISH-Negative ALK. <i>Journal of Thoracic Oncology</i> , 2012, 7, e36-e38.	0.5	87
168	Mucoepidermoid Carcinoma of Tracheobronchial Tree: Clinicopathological Study of 31 Cases. <i>Korean Journal of Pathology</i> , 2011, 45, 175.	1.2	9
169	Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival. <i>BMC Cancer</i> , 2010, 10, 507.	1.1	46
170	One-step Nucleic Acid Amplification (OSNA): Intraoperative Rapid Molecular Diagnostic Method for the Detection of Sentinel Lymph Node Metastases in Breast Cancer Patients in Korean Cohort. <i>Journal of Breast Cancer</i> , 2010, 13, 366.	0.8	3
171	LYN Is a Mediator of Epithelial-Mesenchymal Transition and a Target of Dasatinib in Breast Cancer. <i>Cancer Research</i> , 2010, 70, 2296-2306.	0.4	128
172	Detection of Human Papillomavirus DNA by DNA Chip in Breast Carcinomas of Korean Women. <i>Tumor Biology</i> , 2007, 28, 327-332.	0.8	46
173	Overexpression of CD24: Association With Invasiveness in Urothelial Carcinoma of the Bladder. <i>Archives of Pathology and Laboratory Medicine</i> , 2007, 131, 275-281.	1.2	26
174	Gastric Syphilis Mimicking Adenocarcinoma: A Case Report. <i>Journal of Korean Medical Science</i> , 2006, 21, 559.	1.1	11
175	Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 448, 331-336.	1.4	41
176	Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors. <i>Gynecologic Oncology</i> , 2005, 97, 379-386.	0.6	59
177	HULip, a human homologue of unc-33-like phosphoprotein of <i>Caenorhabditis elegans</i> ; Immunohistochemical localization in the developing human brain and patterns of expression in nervous system tumors. <i>Journal of Neuro-Oncology</i> , 2005, 73, 19-27.	1.4	7
178	Immunoexpression of HBME-1, High Molecular Weight Cytokeratin, Cytokeratin 19, Thyroid Transcription Factor-1, and E-cadherin in Thyroid Carcinomas. <i>Journal of Korean Medical Science</i> , 2005, 20, 853.	1.1	49
179	An Immunohistochemical Study of the Expression of Adhesion Molecules in Gallbladder Lesions. <i>Journal of Histochemistry and Cytochemistry</i> , 2004, 52, 591-601.	1.3	46
180	Cortical laminar disorganization is correlated with severity of the cortical dysplasia and surgical outcomeâ€”experience with 150 cases. <i>Epilepsy Research</i> , 2004, 62, 171-178.	0.8	13

#	ARTICLE	IF	CITATIONS
181	Comparative study of non-functional islet cell tumors and pancreatic solid and papillary neoplasms: Biological behavior and immunohistochemistry. <i>Pathology International</i> , 2002, 52, 358-366.	0.6	11
182	Cytologic clue of so-called nodular histiocytic hyperplasia of the pleura. <i>Diagnostic Cytopathology</i> , 2001, 24, 256-259.	0.5	17
183	Immunoexpression of Inhibin β Subunit, Inhibin/Activin β Subunit and CD99 in Ovarian Tumors. <i>Archives of Pathology and Laboratory Medicine</i> , 2000, 124, 563-569.	1.2	69